Evidence map›Paper›PMID 12390053›Full record

ReviewDrugs & aging2002

Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient.

Timothy F Murphy, Sanjay Sethi

Open access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs & aging, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Factors Contributing to CO Uptake and Elimination in the Body: A Critical Review.International journal of environmental research and public health · 2020
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Timothy F MurphyDivision of Infectious Diseases, University at Buffalo, State University of New York and Department of Veterans Affairs Western New York Health System, Buffalo, USA. murphyt@acsu.buffalo.edu
Sanjay Sethi
University at Buffalo, State University of New York · USVA Western New York Healthcare System · US

Funding

PATHOGENESIS OF BRANHAMELLA CATARRHALIS INFECTIONSR01AI028304 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 1989 to 2009
$2.6M
Recurrent otitis media and COPD: immunity and vaccinesP01AI046422 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2001 to 2004
$2.4M
HAEMOPHILUS ANTIGEN REGULATION OF INFLAMMATION IN COPDR01HL066549 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI SETHI, SANJAY · 2000 to 2003
$881k
Pathogenesis of Moraxella catarrhalis in chronic obstructive pulmonary diseaseR56AI028304 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2010 to 2010
$396k
NHLBI NIH HHS HL66549NIAID NIH HHS AI28304NIAID NIH HHS AI46422
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a common problem in the elderly. The disease is characterised by intermittent worsening of symptoms and these episodes are called acute exacerbations. The best estimate, based on several lines of evidence, is that approximately half of all exacerbations are caused by bacteria. These lines of evidence include studies of lower respiratory tract bacteriology during exacerbations, correlation of airways' inflammation with results of sputum cultures during exacerbations, analysis of immune responses to bacterial pathogens, and the observation in randomised, prospective, placebo-controlled trials that antibacterial therapy is of benefit. The most important bacterial causes of exacerbations of COPD are nontypeable Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae and Chlamydia pneumoniae. In approaching the elderly patient with an exacerbation, it is useful to consider the severity of the exacerbation based on three cardinal symptoms: increased sputum volume, increased sputum purulence and increased dyspnoea compared with baseline. Patients experiencing moderate (two symptoms) or severe (all three symptoms) exacerbations benefit from antibacterial therapy. Consideration of underlying host factors allows for a rational choice of antibacterial agent. Patients are considered to have 'simple COPD' or 'complicated COPD' based on: (i) the severity of underlying lung disease; (ii) the frequency of exacerbations; and (iii) the presence of comorbid conditions. It is proposed that patients with simple COPD are treated with doxycycline, a newer macrolide, or an extended-spectrum oral cephalosporin; and patients with complicated COPD are treated with amoxicillin/clavulanate or a fluoroquinolone. The major goals of antibacterial therapy for exacerbations of COPD are acceleration of symptom resolution and prevention of the complications of exacerbation.

Indexed as

AgedAnti-Bacterial AgentsBacterial InfectionsClinical Trials as TopicGeriatric AssessmentHumansPulmonary Disease, Chronic ObstructiveAnti-Bacterial Agents

Identifiers

PMID12390053
OpenAlexW2106109087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.